Shouldn’t VIVUS Raise Capital Now? (VVUS)

February 23, 2012 · Filed Under Diabetes, fda, Financial, Heart, obesity, Secondary Offering 

While we have started mostly using The Wire at 247wallst.com for our biotech and active trader posts (among many other aspects 50 to 100 times per day), we have a question for BioHealthInvestor readers after VIVUS, Inc. (NASDAQ: VVUS) has basically doubled on news of Qnexa getting a recommendation for approval from a FDA panel…

If you were the CEO or CFO of VIVUS, wouldn’t you immediately go out and raise capital now?

Our take is not just “yes” but a resounding yes.  With $150 million or so in net tangible assets as of September 30, 2011, with a ten-year history, and for many more reasons, this would seem like a shoe-in for a capital raise.

FULL ANALYSIS HERE  

Set your RSS Readers and bookmarks to our Live Wire for continuous financial coverage.

Tags:

Comments

2 Responses to “Shouldn’t VIVUS Raise Capital Now? (VVUS)”

  1. Neilesh on March 5th, 2012 12:01 am

    I came across your blog when googling for cool biotechnology articles – didn’t expect to find this, but enjoyed some of your posts. Keep it up.

  2. Technical Indicator on April 11th, 2012 12:20 pm

    Great work on the Biotech stock analysis Dr Melvin.

    I have enjoyed reading some of your posts and will come back for some more biotech insight soon.

    Thanks

Leave a Reply




    Subscribe to BioHealth Investor BioHealth Investor RSS Feed